These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 30714739)
1. Linear Desferrichrome-Linked Silicon-Rhodamine Antibody Conjugate Enables Targeted Multimodal Imaging of HER2 in Vitro and in Vivo. Ahn SH; Thach D; Vaughn BA; Alford VM; Preston AN; Laughlin ST; Boros E Mol Pharm; 2019 Mar; 16(3):1412-1420. PubMed ID: 30714739 [TBL] [Abstract][Full Text] [Related]
2. Multifunctional Desferrichrome Analogues as Versatile Adams CJ; Wilson JJ; Boros E Mol Pharm; 2017 Aug; 14(8):2831-2842. PubMed ID: 28665620 [TBL] [Abstract][Full Text] [Related]
3. A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing Cho H; Al-Saden N; Lam H; Möbus J; Reilly RM; Winnik MA Nucl Med Biol; 2020; 84-85():11-19. PubMed ID: 31931305 [TBL] [Abstract][Full Text] [Related]
4. Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for Vugts DJ; Klaver C; Sewing C; Poot AJ; Adamzek K; Huegli S; Mari C; Visser GWM; Valverde IE; Gasser G; Mindt TL; van Dongen GAMS Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):286-295. PubMed ID: 27573793 [TBL] [Abstract][Full Text] [Related]
6. Bioorthogonal Fluorophore Linked DFO-Technology Enabling Facile Chelator Quantification and Multimodal Imaging of Antibodies. Meimetis LG; Boros E; Carlson JC; Ran C; Caravan P; Weissleder R Bioconjug Chem; 2016 Jan; 27(1):257-63. PubMed ID: 26684717 [TBL] [Abstract][Full Text] [Related]
7. Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for Raavé R; Sandker G; Adumeau P; Jacobsen CB; Mangin F; Meyer M; Moreau M; Bernhard C; Da Costa L; Dubois A; Goncalves V; Gustafsson M; Rijpkema M; Boerman O; Chambron JC; Heskamp S; Denat F Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1966-1977. PubMed ID: 31161258 [TBL] [Abstract][Full Text] [Related]
8. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with Al-Saden N; Lam K; Chan C; Reilly RM Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952 [TBL] [Abstract][Full Text] [Related]
9. Tripodal tris(hydroxypyridinone) ligands for immunoconjugate PET imaging with (89)Zr(4+): comparison with desferrioxamine-B. Ma MT; Meszaros LK; Paterson BM; Berry DJ; Cooper MS; Ma Y; Hider RC; Blower PJ Dalton Trans; 2015 Mar; 44(11):4884-900. PubMed ID: 25351250 [TBL] [Abstract][Full Text] [Related]
10. Dias GM; Ramogida CF; Rousseau J; Zacchia NA; Hoehr C; Schaffer P; Lin KS; Bénard F Nucl Med Biol; 2018 Mar; 58():1-7. PubMed ID: 29291493 [TBL] [Abstract][Full Text] [Related]
11. p-SCN-Bn-HOPO: A Superior Bifunctional Chelator for (89)Zr ImmunoPET. Deri MA; Ponnala S; Kozlowski P; Burton-Pye BP; Cicek HT; Hu C; Lewis JS; Francesconi LC Bioconjug Chem; 2015 Dec; 26(12):2579-91. PubMed ID: 26550847 [TBL] [Abstract][Full Text] [Related]
12. DFO-Km: A Modular Chelator as a New Chemical Tool for the Construction of Zirconium-89-Based Radiopharmaceuticals. Salih AK; Dominguez Garcia M; Raheem SJ; Ahiahonu WK; Price EW Inorg Chem; 2023 Dec; 62(50):20806-20819. PubMed ID: 37751491 [TBL] [Abstract][Full Text] [Related]
13. In Vivo Characterization of Platinum(II)-Based Linker Technology for the Development of Antibody-Drug Conjugates: Taking Advantage of Dual Labeling with Muns JA; Montserrat V; Houthoff HJ; Codée-van der Schilden K; Zwaagstra O; Sijbrandi NJ; Merkul E; van Dongen GAMS J Nucl Med; 2018 Jul; 59(7):1146-1151. PubMed ID: 29496986 [TBL] [Abstract][Full Text] [Related]
14. Development of Omweri JM; Saini S; Houson HA; Tekin V; Pyles JM; Parker CC; Lapi SE Mol Imaging Biol; 2024 Oct; 26(5):858-868. PubMed ID: 39192059 [TBL] [Abstract][Full Text] [Related]
15. Cyclic versus Noncyclic Chelating Scaffold for Summer D; Garousi J; Oroujeni M; Mitran B; Andersson KG; Vorobyeva A; Löfblom J; Orlova A; Tolmachev V; Decristoforo C Mol Pharm; 2018 Jan; 15(1):175-185. PubMed ID: 29160082 [TBL] [Abstract][Full Text] [Related]
16. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab. Holland JP; Caldas-Lopes E; Divilov V; Longo VA; Taldone T; Zatorska D; Chiosis G; Lewis JS PLoS One; 2010 Jan; 5(1):e8859. PubMed ID: 20111600 [TBL] [Abstract][Full Text] [Related]
17. Site-Specific Yue TTC; Ge Y; Aprile FA; Ma MT; Pham TT; Long NJ Bioconjug Chem; 2023 Oct; 34(10):1802-1810. PubMed ID: 37751398 [TBL] [Abstract][Full Text] [Related]
18. The Influence of Glycans-Specific Bioconjugation on the FcγRI Binding and Vivier D; Fung K; Rodriguez C; Adumeau P; Ulaner GA; Lewis JS; Sharma SK; Zeglis BM Theranostics; 2020; 10(4):1746-1757. PubMed ID: 32042334 [No Abstract] [Full Text] [Related]
19. Positron Emission Tomography Imaging of Platelet-Derived Growth Factor Receptor β in Colorectal Tumor Xenograft Using Zirconium-89 Labeled Dimeric Affibody Molecule. Cai H; Shi Q; Tang Y; Chen L; Chen Y; Tao Z; Yang H; Xie F; Wu X; Liu N; Yang Y; Wu H; Tian R; Lu X; Li L Mol Pharm; 2019 May; 16(5):1950-1957. PubMed ID: 30986347 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and evaluation of novel bifunctional tetrahydroxamate chelators for PET imaging of Rousseau J; Zhang Z; Dias GM; Zhang C; Colpo N; Bénard F; Lin KS Bioorg Med Chem Lett; 2017 Feb; 27(4):708-712. PubMed ID: 28131709 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]